Clovis Oncology (CLVS) Shares Drop As Analysts Give Edge To Lung-Cancer Rival
6/4/2014 7:05:16 AM
It was an American Society of Clinical Oncology meeting to remember for Clovis Oncology, but not in a good way. The sudden fall of the Boulder-based drug company’s stock price was one of the most prominent stories to emerge from the conference, which was held in Chicago over the weekend. Clovis’s (NASDAQ: CLVS) share price fell more than 25 percent the past two days, dropping to $38.23 per share at market close Tuesday after ending last week at $51.21 per share.
Help employers find you! Check out all the jobs and post your resume.
comments powered by